All the previous posts on Pfizer's marketing plans for Lipitor are spurred on by Ranbaxy (in partnership with Teva) gaining FDA approval for manufacturing the generic version at its US plant in New Jersey.
As part of its partnership agreement, Ranbaxy will pay a portion of its sales to Teva during the 180-day exclusivity period. Watson pharmaceuticals will also be selling the officially "approved" version of Lipitor in an agreement with Pfizer during this same period. At the end of the 180 days, up to 6 competitors are expected to be fighting for share in this lucrative market space.
Posted by Bruce Lehr Dec 1st 2011.